DENTSPLY SIRONA Inc designs, develops, manufactures, and markets various dental and oral health products, and other consumable healthcare products primarily for the professional dental market worldwide. The company operates in two segments, Technologies & Equipment; and Consumables. Its dental supplies include endodontic instruments and materials, dental anesthetics, prophylaxis pastes, dental sealants, impression materials, restorative materials, tooth whiteners, and topical fluoride products; and small equipment products comprise dental hand pieces, intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers.
Read More…
Industry, Sector and Symbol
Industry Dental equipment & supplies
Sub-IndustryHealth Care Supplies
SectorMedical
Phone844-546-3722
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.99 billion
Profitability
Miscellaneous
Employees16,400
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
DENTSPLY SIRONA (NASDAQ:XRAY) Frequently Asked Questions
What is DENTSPLY SIRONA's stock symbol?
DENTSPLY SIRONA trades on the NASDAQ under the ticker symbol "XRAY."
How often does DENTSPLY SIRONA pay dividends? What is the dividend yield for DENTSPLY SIRONA?
DENTSPLY SIRONA announced a quarterly dividend on Wednesday, July 31st. Stockholders of record on Friday, September 27th will be paid a dividend of $0.10 per share on Friday, October 11th. This represents a $0.40 annualized dividend and a dividend yield of 0.73%. The ex-dividend date of this dividend is Thursday, September 26th. This is a boost from DENTSPLY SIRONA's previous quarterly dividend of $0.09. View DENTSPLY SIRONA's Dividend History.
How were DENTSPLY SIRONA's earnings last quarter?
DENTSPLY SIRONA Inc (NASDAQ:XRAY) posted its quarterly earnings results on Friday, August, 2nd. The medical instruments supplier reported $0.66 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.62 by $0.04. The medical instruments supplier had revenue of $1.01 billion for the quarter, compared to analysts' expectations of $1.04 billion. DENTSPLY SIRONA had a return on equity of 9.19% and a net margin of 2.67%. DENTSPLY SIRONA's revenue was down 3.1% compared to the same quarter last year. During the same period in the prior year, the business posted $0.60 earnings per share. View DENTSPLY SIRONA's Earnings History.
When is DENTSPLY SIRONA's next earnings date?
What guidance has DENTSPLY SIRONA issued on next quarter's earnings?
DENTSPLY SIRONA updated its FY19 earnings guidance on Friday, August, 2nd. The company provided earnings per share guidance of $2.35-2.45 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.36.
What price target have analysts set for XRAY?
9 analysts have issued 1 year price objectives for DENTSPLY SIRONA's shares. Their predictions range from $49.00 to $63.00. On average, they expect DENTSPLY SIRONA's share price to reach $54.96 in the next year. This suggests a possible upside of 0.9% from the stock's current price. View Analyst Price Targets for DENTSPLY SIRONA.
What is the consensus analysts' recommendation for DENTSPLY SIRONA?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DENTSPLY SIRONA in the last year. There are currently 6 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for DENTSPLY SIRONA.
What are Wall Street analysts saying about DENTSPLY SIRONA stock?
Here are some recent quotes from research analysts about DENTSPLY SIRONA stock:
- 1. Barrington Research analysts commented, "We are now modeling $2.35, up from our prior $2.32 estimate." (8/5/2019)
- 2. According to Zacks Investment Research, "DENTSPLY ended the first quarter on a solid note, with earnings and revenues beating estimates. DENTSPLY gained from the core Technology & Equipment unit, which witnessed a year-over-year upside in the quarter. Sales in the United States also grew year over year. A series of product launches in the quarter buoy optimism in the stock. The company narrowed the EPS guidance for 2019. Meanwhile, DENTSPLY’s Consumable revenues witnessed a year-over-year downside in the quarter. In fact, the company’s quarterly revenues also declined in the first quarter. International revenues decreased on a year-over-year basis as well. Additionally, unfavorable foreign exchange and restructuring costs are expected to mar DENTSPLY’s top line, going forward. The stock is overvalued at the moment." (5/27/2019)
Has DENTSPLY SIRONA been receiving favorable news coverage?
Media coverage about XRAY stock has been trending negative on Tuesday, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. DENTSPLY SIRONA earned a news impact score of -2.1 on InfoTrie's scale. They also gave media stories about the medical instruments supplier a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for DENTSPLY SIRONA.
Are investors shorting DENTSPLY SIRONA?
DENTSPLY SIRONA saw a increase in short interest in September. As of September 15th, there was short interest totalling 4,080,000 shares, an increase of 14.3% from the August 15th total of 3,570,000 shares. Based on an average daily volume of 1,690,000 shares, the short-interest ratio is presently 2.4 days. Currently, 1.8% of the company's shares are short sold. View DENTSPLY SIRONA's Current Options Chain.
Who are some of DENTSPLY SIRONA's key competitors?
Some companies that are related to DENTSPLY SIRONA include Align Technology (ALGN), Cooper Companies (COO), West Pharmaceutical Services (WST), Haemonetics (HAE), Neogen (NEOG), ICU Medical (ICUI), Quidel (QDEL), Merit Medical Systems (MMSI), Atrion (ATRI), STAAR Surgical (STAA), Anika Therapeutics (ANIK), Cerus (CERS), Antares Pharma (ATRS), OraSure Technologies (OSUR) and Meridian Bioscience (VIVO).
What other stocks do shareholders of DENTSPLY SIRONA own?
Who are DENTSPLY SIRONA's key executives?
DENTSPLY SIRONA's management team includes the folowing people:
- Mr. Nicholas William Alexos, Exec. VP & CFO (Age 55)
- Mr. Keith John Ebling, EVP, Gen. Counsel & Sec. (Age 50)
- Ms. Maureen J. MacInnis, Sr. VP, Chief HR Officer & Communications (Age 58)
- Mr. Donald M. Casey Jr., CEO & Director (Age 59)
- Mr. Dominique P. Legros, Sr. VP of Equipment, Technologies & Healthcare Segment (Age 59)
Who are DENTSPLY SIRONA's major shareholders?
DENTSPLY SIRONA's stock is owned by many different of institutional and retail investors. Top institutional investors include Robeco Institutional Asset Management B.V. (0.51%), Douglas Lane & Associates LLC (0.29%), Boston Trust Walden Corp (0.21%), Robecosam AG (0.18%), John G Ullman & Associates Inc. (0.10%) and Commerzbank Aktiengesellschaft FI (0.08%). Company insiders that own DENTSPLY SIRONA stock include Betsy D Holden, Daniel P Key, Donald M Jr Casey, Eric Brandt, Francis J Lunger, Gregory T Lucier, Mark Thierer, Markus Boehringer, Maureen J Macinnis, Michael C Alfano, Michael J Coleman, Nicholas W Alexos and William E Newell. View Institutional Ownership Trends for DENTSPLY SIRONA.
Which major investors are selling DENTSPLY SIRONA stock?
XRAY stock was sold by a variety of institutional investors in the last quarter, including DNB Asset Management AS, Douglas Lane & Associates LLC, Zurcher Kantonalbank Zurich Cantonalbank , Robecosam AG, Stonebridge Capital Management Inc., Meeder Asset Management Inc., Farmers & Merchants Investments Inc. and Gateway Investment Advisers LLC. Company insiders that have sold DENTSPLY SIRONA company stock in the last year include Eric Brandt, Markus Boehringer, Maureen J Macinnis, Michael J Coleman and William E Newell. View Insider Buying and Selling for DENTSPLY SIRONA.
Which major investors are buying DENTSPLY SIRONA stock?
XRAY stock was purchased by a variety of institutional investors in the last quarter, including Robeco Institutional Asset Management B.V., State of Alaska Department of Revenue, Nisa Investment Advisors LLC, Boston Trust Walden Corp, Wealthfront Advisers LLC, Campbell & CO Investment Adviser LLC, Tributary Capital Management LLC and Whittier Trust Co.. Company insiders that have bought DENTSPLY SIRONA stock in the last two years include Betsy D Holden, Daniel P Key, Donald M Jr Casey, Gregory T Lucier, Mark Thierer and Nicholas W Alexos. View Insider Buying and Selling for DENTSPLY SIRONA.
How do I buy shares of DENTSPLY SIRONA?
Shares of XRAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is DENTSPLY SIRONA's stock price today?
One share of XRAY stock can currently be purchased for approximately $54.50.
How big of a company is DENTSPLY SIRONA?
DENTSPLY SIRONA has a market capitalization of $12.22 billion and generates $3.99 billion in revenue each year. The medical instruments supplier earns $-1,011,000,000.00 in net income (profit) each year or $2.01 on an earnings per share basis. DENTSPLY SIRONA employs 16,400 workers across the globe.View Additional Information About DENTSPLY SIRONA.
What is DENTSPLY SIRONA's official website?
How can I contact DENTSPLY SIRONA?
DENTSPLY SIRONA's mailing address is 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC, 28277. The medical instruments supplier can be reached via phone at 844-546-3722 or via email at [email protected]
MarketBeat Community Rating for DENTSPLY SIRONA (NASDAQ XRAY)
MarketBeat's community ratings are surveys of what our community members think about DENTSPLY SIRONA and other stocks. Vote "Outperform" if you believe XRAY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XRAY will underperform the S&P 500 over the long term. You may vote once every thirty days.
